Systematic Review: Intravenous Ibuprofen in Preterm Newborns

Seminars in Perinatology

Volumn 30, Issue 3, 2006, Pages 114-120

  Aranda, J V ^a   Thomas, Ronald ^a  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

Author keywords

ibuprofen; indomethacin; nonsteroidal antiinflammatory drugs; NSAIDs; patent ductus arteriosus; premature newborn infant

Indexed keywords

2 HYDROXYIBUPROFEN; AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; ANTIPYRETIC AGENT; BILIRUBIN; CARBOXYIBUPROFEN; DRUG METABOLITE; HYDROCORTISONE; IBUPROFEN; IBUPROFEN ACYLGLUCURONIDE; IBUPROFEN DERIVATIVE; IBUPROFEN LYSINE; IBUPROFEN THAM; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; STEROID; UNCLASSIFIED DRUG;

ARTERY CONSTRICTION; ARTERY LIGATION; ARTHRITIS; BIOENERGY; BLEEDING DISORDER; BLOOD TOXICITY; BRAIN BLOOD FLOW; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG TREATMENT FAILURE; DUCTUS ARTERIOSUS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEMODYNAMICS; HUMAN; INCIDENCE; INTESTINE PERFORATION; ISCHEMIA; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LAMB; LUNG TOXICITY; MESENTERY BLOOD FLOW; NECROTIZING ENTEROCOLITIS; NEPHROTOXICITY; NEWBORN DISEASE; NONHUMAN; OLIGURIA; OUTCOME ASSESSMENT; PATENT DUCTUS ARTERIOSUS; PEPTIC ULCER; PERINATAL PERIOD; PREMATURITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR; SIDE EFFECT; STEROID THERAPY; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; VASOCONSTRICTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DUCTUS ARTERIOSUS, PATENT; FEMALE; HUMANS; IBUPROFEN; INDOMETHACIN; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; INJECTIONS, INTRAVENOUS; MALE; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 33745248045     PISSN: 01460005     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semperi.2006.04.003     Document Type: Review

References (56)

1. Coceani F., White E., Bodach E., et al. Age dependent changes in the response of the lamb ductus arteriosus to oxygen and ibuprofen. Can J Physiol Pharmacol 57 (1979) 825-831
2. Chemtob S., Beharry K., Rex J., et al. Prostanoids determine the range of cerebral blood flow autoregulation of newborn piglets. Stroke 21 (1990) 777-784
3. Chemtob S., Beharry K., Barna T., et al. Differences in the effects in the newborn piglet of various nonsteroidal antiinflammatory drugs on cerebral blood flow but not on cerebrovascular prostaglandins. Pediatr Res 30 (1991) 106-111
4. Varvarigou A., Bardin C.L., Beharry K., et al. Early ibuprofen administration to prevent patent ductus arteriosus in premature newborn infants. J Am Med Assoc 275 (1996) 539-544
5. Gournay V., Roze J.C., Kuster A., et al. Prophylactic ibuprofen versus placebo in very premature infants. a randomized, double-blind, placebo-controlled trial. Lancet 364 (2004) 1939-1944
6. Gournay V., Savagner C., Thiriez G., et al. Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants. Lancet 359 (2002) 1486-1488
7. DeCarolis M.P., Romagnoli C., Polimeni V., et al. Prophylactic ibuprofen therapy of patent ductus arteriosus in preterm infants. Eur J Pediatr 159 (2000) 364-368
8. Van Overmeire B., Allegaert K., Casaer A., et al. Prophylactic ibuprofen in premature infants. a multicentre, randomized, double blind, placebo-controlled trial. Lancet 364 (2004) 1945-1949
9. Naulaers G., Delanghe G., Allegaert K., et al. Ibuprofen and cerebral oxygenation and circulation. Arch Dis Child Fetal Neonatal Ed 90 (2005) F75-F76
10. Aranda JV and Intravenous Ibuprofen Multicenter Trials Team. Presented to Pediatric Academic Societies Meeting, Washington DC, May 2005
11. Dani C., Bertini G., Reali M.F., et al. Prophylaxis of patent ductus arteriosus with ibuprofen in preterm infants. Acta Paediatr 89 (2000) 1369-1374
12. Patel J., Marks K.A., Roberts I., et al. Ibuprofen treatment of patent ductus arteriosus. Lancet 346 (1995) 255
13. Patel J., Roberts I., Azzopardi D., et al. Rndomized double-blind controlled trial comparing the effects of ibuprofen with Indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus. Pediatr Res 47 (2000) 36-42
14. Van Overmeire B., Follens I., Hartmann S., et al. Treatment of patent ductus arteriosus with ibuprofen. Arch Dis Child Fetal Neonatal Ed 76 (1997) F179-F184
15. Van Overmeire B., Smets K., Lecoutere D., et al. A comparison of ibuprofen and Indomethacin for closure of patent ductus arteriosus. N Engl J Med 343 (2000) 674-681
16. Lago P., Bettiol T., Slavadori S., et al. Safety and efficacy of ibuprofen versus Indomethacin in preterm infants treated for patent ductus arteriosus. a randomized controlled trial. Eur J Pediatr 161 (2002) 202-207
17. Mosca F., Bray M., Lattanzio M., et al. Compartive evaluation of the effects of Indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arteriosus. J Pediatr 131 (1997) 549-554
18. Pezzati M., Vangi V., Biagiotti R., et al. Effects of Indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus. J Pediatr 135 (1999) 733-738
19. Plavka R., Svihovec P., Borek I., et al. Ibuprofen vs indomethacin in the treatment of patent ductus arteriosus in very premature neonates. Pediatr Res 49 (2001) 375A
20. Su P.H., Chen J.Y., Su C.M., et al. Comparison of ibuprofen and Indomethacin therapy for patent ductus arteriosus in preterm infants. Pediatr Int 45 (2003) 665-670
21. Mosca F., Bray M., Colnaghi M.R., et al. Cerebral vasoreacticity to arterial carbon dioxide tension in preterm infants. the effect of ibuprofen. J Pediatr 135 (1999) 644-646
22. Romagnoli C., DeCarolis M.P., Papacci P., et al. Effects of prophylactic ibuprofen on cerebral and renal hemodynamics in very preterm neonates. Clin Pharmacol Ther 67 (2000) 676-683
23. DeCarolis M.P., Romagnoli C., Polimeni V., et al. Prophylactic ibuprofen therapy of patent ductus arteriosus in preterm infants. Eur J Pediatr 159 (2000) 364-368
24. Chotigeat U., Jirapapa K., and Layangkool T. A comparison of oral ibuprofen and intravenous Indomethacin for closure of patent ductus arteriosus in preterm infants. J Med Assoc Thai 86 suppl 3 (2004) S563-S569
25. Supapannachart S., Limrungsikul A., and Khowsathit P. Oral ibuprofen and Indomethacin for treatment of patent ductus arteriosus in premature infants. a randomized trial at Ramathibodi Hospital. J Med Assoc Thai 85 suppl 4 (2002) S1252-S1258
26. Heyman E., Morag I., Batash D., et al. Closure of patent ductus arteriosus with oral ibuprofen suspension in premature newborns. a pilot study. Pediatrics 112 (2003) e354
27. Hariprasad P., Sundarrajan V., Srimathy G., et al. Oral ibuprofen for closure of hemodynamically significant PDA in premature neonates. Indian Pediatr 39 (2002) 99-100
28. Thomas R.L., Parker G.C., Van Overmeire B., et al. A meta-analysis of ibuprofen versus indomethacine for closure of patent ductus arteriosus. Eur J Pediatr 164 (2005) 135-140
29. Shah S.S., and Ohlsson A. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2 (2003) CD004213
30. Ohlsson A., Walia R., and Shah S. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2 (2003) CD003481
31. Wright D.H., Abran D., Bhattacharya M., et al. Prostanoid receptors. ontogeny and implications in vascular physiology. Am J Physiol Regul Integr Comp Physiol 281 (2001) R1343-R1360
32. Fanos V., Benini D., Verlato G., et al. Efficacy and renal tolerability of ibuprofen vs. Indomethacin in preterm infants with patent ductus arteriosus. Fundament Clin Pharmacol 19 (2005) 187-193
33. Dani C., Bertini G., Pezzati M., et al. Prophylactic ibuprofen for the prevention of intraventricular hemorrhage among preterm infants; a multicenter, randomized study. Pediatrics 115 (2005) 1529-1535
34. Aranda J.V., Varvarigou A., Beharry K., et al. Pharmacokinetics and protein binding of intravenous ibuprofen in the premature newborn infant. Acta Paediatr 86 (1997) 289-293
35. Desfrere L., Zohar S., Morville P., et al. Dose-finding study of ibuprpfen in patent ductus arteriosus using the continual reassessment method. J Clin Pharm Ther 30 (2005) 121-132
36. Davies N.M. Clinical pharmacokinetics of ibuprofen. The first 30 years. Clin Pharmacokinet 34 (1998) 101-154
37. Van Overmeire B., Touw D., Schepens P.J., et al. Ibuprofen pharmacokinetics in preterm infants with patent ductus arteriosus. Clin Pharmacol Ther 70 (2001) 336-343
38. Gregoire N., Gualano V., Geneteau A., et al. Population pharmacokinetics of ibuprofen enantiomers in very premature neonates. J Clin Pharmacol 44 (2004) 1114-1124
39. Sharma P.K., Garg S.K., and Narang A. Pharmacokinetics of oral ibuprofen in premature infants. J Clin Pharmacol 43 (2003) 968-973
40. Peng S., and Duggan A. Gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Expert Opin Drug Saf 4 (2005) 157-169
41. Tatli M.M., Kumral A., Duman N., et al. Spontaneous intestinal perforation after oral ibuprofen treatment of patent ductus arteriosus in two very-low-birthweight infants. Acta Paediatr 93 (2004) 999-1001
42. Stark A.R., Carlo W.A., Tyson J.E., et al. Adverse effects of early dexamethasone in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 344 (2001) 95-101
43. Watterberg K.L., Gerdes J.S., Cole C.H., et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia. a multicenter trial. Pediatrics 114 (2004) 1649-1657
44. Garland J.S., Alex C.P., Pauly T.H., et al. A three-day course of dexamethasone therapy to prevent chronic lung disease in ventilated neonates. a randomized trial. Pediatrics 104 (1999) 91-99
45. Peltoniemi O., Kari M.A., Heinonen K., et al. Pretreatment cortisol values may predict responses to hydrocortisone administration for the prevention of bronchopulmonary dysplasia in high-risk infants. J Pediatr 146 (2005) 63207
46. Cooper-Peel C., Brodersen R., and Robertson A. Does ibuprofen affect bilirubin-albumin binding in newborn infant serum?. Pharmacol Toxicol 79 (1996) 297-299
47. Ahlfors C.E. Effect of ibuprofen on bilirubin-albumin binding. J Pediatr 144 (2004) 386-388
48. Ambat M.T.C., Ostrea Jr. E.M., and Aranda J.V. Influence of ibuprofen l-lysinate (IBU) on bilirubin binding to albumin. Pediatr Res 51 (2002) 344A
49. Ambat M.T.C., Ostrea Jr. E.M., and Aranda J.V. Influence of ibuprofenl-lysinate (IBU) on bilirubin albumin binding as determined by the saturation index and horseradish peroxidase tests. Pediatr Res 53 (2003) 365A
50. Van Overmeire B., Vanhagendoren S., Schepens P.J., et al. The influence of ibuprofen-lysine on unbound bilirubin plasma levels in preterm neonates. Pediatr Res 55 (2004) 474A
51. Mosca F., Bray M., Stucchi I., et al. Pulmonary hypertension after ibuprofen prophylaxis in the very preterm infants. Lancet 360 (2002) 1023-1024
52. Allegaert K., Cossey V., Langhendries J.P., et al. Effects of co-administration of ibuprofen-lysine on the pharmacokinetics of amikacin in preterm infants during the first days of life. Biol Neonate 86 (2004) 207-211
53. Bray M., Stucchi I., Fumagalli M., et al. Blood withdrawal and infusion via umbilical catheters. effect on cerebral perfusion and influence of ibuprofen. Biol Neonate 84 (2003) 187-193
54. Guignard J.P. The adverse renal effects of prostaglandin-synthesis inhibitors in the newborn rabbit. Semin Perinatol 26 (2002) 398-405
55. Drukker A., and Guignard J.P. Ibuprofen-lysine for closure of patent ductus arteriosus. Acta Paediatr 90 (2001) 465-466
56. Chamaa N.S., Mosig D., Drukker A., et al. The renal hemodynamic effects of ibuprofen in the newborn rabbit. Pediatr Res 48 (2000) 600-605